BT BUSINESSES
Introducing BT sector affiliates within the dooroo group.
Founded in 2001, Dooroo Pharm. grew into a company recording sales of USD 132.5 mil (2015) in just 10 years based on the financial strength of Dooroo Chemicals, its parent company. Ranking within the top 20 firms in the industry, it acquired Dong-Yang MST in 2012, and invested in BioCND in 2013. From its core industry of distribution of pharmaceuticals, it is expanding its business areas to the development of biopharmaceuticals through M&A and founding subsidiaries
Address 15, Maeheon-ro 6-gil, Seocho-gu, Seoul, Korea
|
TEL +82-2-792-7694
|
FAX +82-2-792-3447
Sales through large hospitals and retail are in the distribution sphere while those through the rare diseases market exclusive sales, and local hospitals are CSO businesses.
1. Rare Diseases Market
Dooroo Pharm is recording CSO sales in the rare diseases market.
2. Exclusive Sales
Dooroo Pharm is recording sales through CSO.
3. Local Hospital Market
Major items : Vaccines, well-being products (vitamin shots, placenta shots, etc.), antibiotics, cosmetics (filler, breast augmentation, vaginal surgery etc.), amino acid supplement, etc.
We have created a distribution network that includes approximately 500 local hospitals and are rapidly growing by raising CSO sales.
Address 15, Maeheon-ro 6-gil, Seocho-gu, Seoul, Korea
|
TEL +82-2-571-0086
|
FAX +82-2-792-3447
JL BioLab Corp. is leading the improvement of public health and quality of life by satisfying new pharmaceutical needs of patients
and medical professionals such as treating hepatitis type B through marketing of Entecavir ODF.
Founded in 2002, Dong-Yang MST has grown as a major supplier to Soon Chun Hyang University Hospital (SCUH) which has branches all over Korea. After being acquired by Dooroo in 2012, it is developing further by supplying to the National Cancer Center and the Seoul National University Hospital.
Address 38, Dokseodang-ro, Yongsan-gu, Seoul, Korea
|
TEL +82-2-794-7011
|
FAX +82-2-797-8080